

*Curriculum Vitae*  
**Juliet K. Knowles, M.D, Ph.D.**

Palo Alto, CA 94304

jdk1@stanford.edu

(650) 521-2932

Lab website: [med.stanford.edu/pedsepilepsy-lab](http://med.stanford.edu/pedsepilepsy-lab)

March 10, 2022

### **Professional Experience**

Assistant Professor, Pediatric Neurology and Epilepsy Stanford Children's Hospital	5/2021 - present
Instructor, Pediatric Neurology and Epilepsy Stanford Children's Hospital	7/2018 – 5/2021
Pediatric Epilepsy Fellow Stanford Children's Hospital	7/2016 - 6/2018
Chief Resident Stanford University Hospital, Department of Neurology	7/2015 - 6/2016
Residency, Pediatrics and Pediatric Neurology Stanford Children's Hospital / Stanford University Hospital	7/2012 - 6/2016
Internship, Pediatrics Stanford Children's Hospital	6/2011 - 6/2012

### **Board Certification**

American Board of Psychiatry and Neurology, Certification in Neurology with Special Qualifications in Child Neurology	9/2016
American Board of Psychiatry and Neurology, Certification in Epilepsy	10/2018

### **Education**

M.D., Stanford University School of Medicine	6/2011
Ph.D., Stanford University Neurosciences Graduate Program	9/2009
MSTP, University of North Carolina – Chapel Hill (transferred to Stanford for remainder of MD/PhD training)	8/2001 - 8/2005
B.A., Microbiology & Philosophy; Minor in French University of Texas at Austin	5/2001
Study abroad, University of Paris (France)	8/1999 - 6/2000

### **Competitive Research Funding**

NIH-NINDS K08 NS119800 <i>Maladaptive Myelination in Pediatric Epilepsy</i> Role: PI	9/2021-8/2026
NIH-NINDS K12 NS098482 (Child Neurologist Career Development Program) <i>Impact of Recurrent Seizures Upon Myelin Structure and Function</i> Role: PI	7/2018 - 6/2021
Child Neurology Foundation/Pediatric Epilepsy Research Foundation Elterman Award. <i>Targeting Aberrant Activity-dependent Myelination in Absence Epilepsy</i> Role: PI	1/2021 – 12/2023
NIH/NHLBI R01 HL 152757 <i>Neurometabolic outcomes of Different Cardiopulmonary Bypass Strategies</i> Role: co-I with PIs Drs. Frank Hanley and Kirk Riemer	3/2021 – 2/2026
Citizens United for Research in Epilepsy (CURE)-Covid Research Continuity Award. Role: PI	12/2020
Citizens United for Research in Epilepsy (CURE) Taking Flight Award <i>Abnormal myelination in absence epilepsy: cause and functional impact</i> Role: PI	10/2018 - 4/2020
Stanford Maternal and Children's Health Research Institute (MCHRI) Pilot Grant <i>Impact of Recurrent Seizures Upon Myelin Structure and Function</i> Role: PI	7/2018 - 6/2019
Stanford MCHRI K support award. Role: PI	7/2018 - 6/2020
American Epilepsy Society Clinical Translational Research Fellowship <i>Impact of Recurrent Seizures Upon Myelin Structure and Plasticity</i> Role: PI	7/2016 - 6/2017
NIH-NINDS F30 Pre-doctoral Fellowship <i>P75NTR-mediated protection from amyloid neurodegeneration</i> Role: co-PI (with PhD mentor Dr. Frank Longo)	6/2006 - 6/2009

## Honors and Awards

Johns Hopkins University Stroup Award for "Rising Star" in Pediatric Epilepsy Research	2021
---	------

## Stanford University School of Medicine

First place, Stanford Neuroscience Forum (Resident Research Day)	2015
Stanford Society of Physician Scholars	2014

First place, Stanford Neuroscience Forum 2013  
Northern California Alzheimer's Association Outstanding Young Scientist 2009

### **University of North Carolina at Chapel Hill School of Medicine**

First place, Neuroscience Center Pierre Morrell Research Day 2004  
Summer Research Scholarship, American Academy of Neurology 2004  
Frank Porter Graham Honor Society 2004  
Order of the Grail-Valkyries Honor Society 2004  
Social Medicine Paper Prize 2003  
Eugene S. Mayer Community Service Honor Society 2003  
John B. Graham Student Research Society 2003  
Loyalty Fund Scholarship 2001 - 2003

### **University of Texas at Austin**

Phi Beta Kappa 2001  
Graduated with Honors 2001  
Honors Research Thesis in Neurobiology 2001  
College Scholar (Honor Roll for Academic Year) 1997 - 2001  
Margaret Jane McKinney Fellowship in Bacteriology 2001  
National Leadership Award for Outstanding Collegian, Alpha Xi Delta Sorority, based on service as UT-Austin Chapter President (1998) and Vice President (1997) 2001

### **Peer Reviewed Publications (Original Research)**

1. **Knowles JK\***, Xu H, Soane C, Batra A, Saucedo T, Frost E, Tam L, Fraga D, Villareal K, Huguenard J\*, Monje M\*. Maladaptive Myelination Contributes to Generalized Epilepsy Progression. **Accepted**, *Nature Neuroscience* 2022. \*co-corresponding author. (an earlier vision of this manuscript is on BioRxiv at <https://www.biorxiv.org/content/10.1101/2020.08.20.260083v1>)
2. Pavitt S, Carley A, Porter B, **Knowles JK**. A Standardized Protocol to Improve Management of Acute Seizures in the Pediatric Epilepsy Monitoring Unit. *Hospital Pediatrics*, 2021. PMID: 33685859.

3. Sandoval Karamian AG, Wusthoff CJ, Boothroyd D, Yeom KW, **Knowles JK**. Neonatal genetic epilepsies display convergent white matter microstructural abnormalities. *Epilepsia*, 2020. PMID: 33098118.
4. **Knowles JK**, Santoro JD, Porter BE, Baumer FM. Refractory Focal Epilepsy in a Paediatric Patient with Primary Familial Brain Calcification. *Seizure*, February 2018. PMID: 29448117.
5. Simmons DA, Knowles JK, Belichenko NP, Banerjee G, Finkle C, Massa SM, Longo FM. A small molecule p75<sup>NTR</sup> ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. *PLoS One*, August 2014. PMID: 25153701.
6. **Knowles JK**, Simmons DA, Nguyen T-V, Vander Griend L, Xie Y, Zhang H, Yang T, Pollak J, Chang T, Arancio O, Buckwalter M, Wyss-Coray T, Massa SM, Longo FM. A small molecule p75<sup>NTR</sup> ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. *Neurobiology of Aging*, August 2013. PMID 23545424.
7. **Knowles JK**, Rajadas J, Vander Griend L, Ishikawa C, Nguyen T, LeMieux M, Wyss-Coray T, Longo FM. The p75 neurotrophin receptor promotes amyloid- $\beta$ (1-42) induced neuritic dystrophy *in vitro* and *in vivo*. *The Journal of Neuroscience*, August 2009. PMID 19710315.
8. Yang T\*, **Knowles JK\***, Lu Q, Zhang H, Arancio O, Moore L, Chang T, Wang Q, Andreasson K, Rajadas J, Fuller G, Xie Y, Massa SM, Longo FM. Small molecule, non-peptide p75<sup>NTR</sup> ligands inhibit A $\beta$ -induced neurodegeneration and synaptic impairment. *PLoS One*, October 2008. PMID 18978948. \*co-first author
9. Prip-Buus C, Thuillier L, Abadi N, Prasad C, Dilling L, **Klasing J**, Demaugre F, Greenberg CR, Haworth JC, Droin V, Kadhom N, Gobin S, Kamoun P, Girard J, Bonnefont JP. Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community. *Molecular Genetics and Metabolism*, May 2001. PMID 11350182.

## Book Chapters and Reviews

1. **Knowles JK**, Porter BE. Practical Advice on Surviving and Thriving as an Academic Physician-Neuroscientist. *JAMA Neurology*, 2021. PMID: 34694341.
2. **Knowles JK\***, Helbig I\*, Metcalf C\*, Lubbers, LS, Isom LL, Demarest S, Goldberg E, George AL, Lerche H, Weckhuysen S, Whittemore V, Berkovic SF, and Lowenstein DH. Precision medicine for genetic epilepsy on the horizon: recent advances, present challenges and suggestions for continued progress. In revision at *Epilepsia*.
3. Adaptive and maladaptive myelination in health and disease. **Knowles JK**, Batra A, Xu H and Monje M. Under review at *Nature Reviews Neurology*.
4. **Knowles JK**, Wusthoff CJ. Quantitative EEG in Neonatal Seizures. In: Husain A, Sinha S (eds) Continuous EEG Monitoring. Springer, 2017.

5. **Knowles JK**, Penn AA. Perinatal Brain Development, Malformation and Injury. Morgan and Claypool Life Sciences Colloquium Series on the Developing Brain, 2012.
6. Longo FM, Yang T, **Knowles JK**, Xie Y, Moore LA, Massa SM. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms. *Current Alzheimer Research*, 2007. PMID 18220511.

## Presentations

1. *"Maladaptive Myelination in Pediatric Epilepsy."* Invited speaker, American Epilepsy Society, December 2021.
2. *"Maladaptive Myelination in Pediatric Epilepsy."* Radiology Science Laboratories seminar, Stanford University, April 2021.
3. *"Maladaptive Myelination in Pediatric Epilepsy."* Johns Hopkins Stroup Award lecture, March 2021.
4. *"Maladaptive Myelination in Pediatric Epilepsy."* Stanford MCHRI joint seminar with Michelle Monje, March 2021.
5. *"Abnormal white matter in neonates with nonstructural epilepsy."* Senior author, poster at American Epilepsy Society meeting 2020.
6. *"Maladaptive myelination contributes to epileptogenesis."* Selected speaker, Cold Spring Harbor meeting, Glia in Health and Disease 2020.
7. *"Aberrant Activity-Dependent Myelination in Epilepsy."* First author, Child Neurology Society meeting 2020.
8. *"A standardized protocol to improve acute seizure management in the Pediatric EMU."* Senior author, poster at the Child Neurology Society meeting 2020.
9. *"Precision Medicine in Pediatric Genetic Epilepsy."* Stanford Children's Health, presentation to families of children with epilepsy 2020.
10. *"Maladaptive Myelination in Pediatric Epilepsy."* Annual presentation to the national Child Neurologist Career Development Program – K12 (NIH/NINDS) Committee: 2018, 2019, 2020.
11. *"Maladaptive Myelination in Epilepsy."* Invited speaker, Epilepsy Precision Medicine National Meeting, Washington DC, 2019.
12. *"Maladaptive Myelination in Epilepsy."* Invited speaker, University of Iowa Department of Pediatrics, 2019.
13. *"Improving Acute Seizure Management in the Pediatric Epilepsy Monitoring Unit."* Senior author, Stanford Resident Quality Improvement/Patient Safety Symposium, 2019.
14. *"Impact of Recurrent Seizures on Myelin Structure and Function."* American Epilepsy Society Annual International meeting, 2017.

15. "Impact of Recurrent Seizures on Myelin Structure and Plasticity." Stanford University Neurology Grand Rounds, 2016.
16. "Genetic and Optogenetic Models to Investigate the Impact of Recurrent Seizures on Myelin Plasticity." Stanford University Neuroscience Research Forum, 2015.
17. "A Pediatric Case of Acute Flaccid Monoplegia." Stanford Department of Neurology Grand Rounds, 2014.
18. "A small molecule p75<sup>NTR</sup> ligand prevents cognitive deficits and neurite degeneration in vivo." Stanford University Neuroscience Research Forum, 2013.
19. "A small molecule p75<sup>NTR</sup> ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model." Society for Neuroscience international annual meeting, New Orleans, 2012.
20. "The p75 neurotrophin receptor promotes amyloid- $\beta$ (1-42) induced neuritic dystrophy in vitro and in vivo." Society for Neuroscience international annual meeting, Chicago 2009.
21. Selected speaker, "Novel Small Molecule p75<sup>NTR</sup> Ligands Prevent A $\beta$ -induced Neurodegeneration" Molecular Mechanisms of Neurodegeneration international meeting organized by Dr. Rudy Tanzi, Antigua, 2007.
22. "Small Molecule Mimetics of NGF Loop 1 are Candidate Novel Alzheimer's Disease Therapeutics" UNC Chapel Hill Neuroscience Center, Pierre Morrell Research Day, 2004.
23. "A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub> Peptides are Partial Agonists of the  $\alpha$ 7 Nicotinic Acetylcholine Receptor," UNC Medical Student Research Day, 2003.

## Scholarly Research

### 2018 - present: **Maladaptive myelination in epilepsy.**

Structural and functional changes in neural networks underlie epileptogenesis and cognitive dysfunction in multiple forms of epilepsy. However, these pathological changes are incompletely understood and, as a result, there are no disease-modifying therapies for epilepsy. Myelin plasticity is a newly recognized dimension of activity-dependent neural network adaptation that occur throughout the lifespan. Numerous studies in humans and animals indicate that neuronal activity influences myelin structure; this activity-regulated myelination in turn, sculpts neuronal network function, and is an adaptive process that is required for multiple forms of learning. The potential role of activity-regulated myelination in disease states characterized by persistent and abnormal patterns of neuronal activity, such as epilepsy, is unknown. **I hypothesized that in epilepsy, pathological patterns of neuronal activity may also influence myelin to alter network function; aberrant increases or decreases in myelination could in turn, contribute to epilepsy pathogenesis.**

Using quantitative histological, electron microscopy and neurophysiological techniques, my research has identified aberrantly increased myelination of seizure network projections in multiple rodent models of generalized epilepsy. Blockade of seizures with the drug ethosuximide prevented the abnormal myelination, indicating that seizures are required for these abnormalities. Conditional genetic blockade of activity-dependent myelin plasticity in a mouse model of generalized epilepsy prevented progression of absence seizures that is characteristic of animal models of generalized epilepsy. Furthermore, pharmacological blockade of myelin plasticity, initiated after seizure onset, also prevented seizure progression. This is the first

demonstration that activity-dependent myelination can become *maladaptive* to promote progression of seizures. These discoveries suggest that maladaptive myelination is a novel pathogenic mechanism which may be applicable in multiple other forms of epilepsy and other neurological and neuropsychiatric diseases. **My first author/corresponding author manuscript describing these findings has been accepted at *Nature Neuroscience*.**

In my independent laboratory, my team and I are developing research directions that build on this work including 1. High-resolution diffusion-based MR imaging of humans and rodent models of epilepsy in collaboration with Stanford Radiology faculty researcher Dr. Jennifer McNab, as well as CLARITY and related methods, for high resolution visualization of whole brain myelination; 2. cellular and molecular mechanisms underlying abnormal myelination in epilepsy models; 3. further functional investigation of abnormal myelination at the circuit and network level using a range of neurophysiological techniques; 4. the role of abnormal myelination in multiple forms of pediatric epilepsy and other diseases characterized by abnormal neuronal activity, and cognitive co-morbidities; 5. therapeutic strategies to target abnormal myelination.

**2018 - 2021: *Aberrant white matter in neonatal genetic epilepsy.***  
**Mentor/senior author.**

In parallel to the laboratory efforts detailed above, I mentored resident physician Dr. Amanda Sandoval Karamian (Stanford Child Neurology) on a clinical project investigating white matter in neonates with nonstructural/genetic epilepsy. We found white matter structural abnormalities in association with seizures, which parallel my findings in rodent models. This work was presented at the 2020 American Epilepsy Society meeting and was published in *Epilepsia*.

**2003 - 2009: *p75<sup>NTR</sup>-mediated protection from  $\beta$ -amyloid induced neurodegeneration.***  
**Doctoral thesis, laboratory of Dr. Frank Longo at Stanford.**

The p75 neurotrophin receptor (p75<sup>NTR</sup>) is expressed on neuron populations which degenerate in Alzheimer's disease (AD), is upregulated in the disease, and induces neurodegeneration under many circumstances. I tested the hypothesis that p75<sup>NTR</sup> modulates AD-like amyloid (A $\beta$ )-induced neurodegeneration using p75<sup>NTR</sup> +/+ and -/- neuron cultures and p75<sup>NTR</sup> -/-, mutant amyloid precursor protein (APP) transgenic mice modeling AD. Both *in vitro* and *in vivo*, p75<sup>NTR</sup> signaling contributes significantly to A $\beta$ -induced deleterious effects. In addition to degenerative signaling, p75<sup>NTR</sup> is also capable of pro-survival signaling via the PI3K/Akt pathway, which is known to inhibit major signaling cascades in A $\beta$ -induced degeneration. A strategy to shift p75<sup>NTR</sup> signaling toward pro-survival pathways could block A $\beta$ -induced neurodegeneration. We tested this hypothesis using novel small molecule ligands which bind to p75<sup>NTR</sup> to activate Akt and promote neuron survival. My work demonstrated that, in neuron culture and hippocampal slices, p75<sup>NTR</sup> ligands were potent neuroprotectives that prevented multiple A $\beta$ -induced deleterious effects. I further demonstrated that treatment of transgenic mouse models of AD with an orally bioavailable lead p75<sup>NTR</sup> ligand, LM11A-31, significantly reduced hippocampal, cholinergic basal forebrain and cortical neuritic dystrophy relative to vehicle treated mice and improved cognitive performance in the Novel Object Recognition and Y maze behavioral tests. These findings led to a recently completed, successful Phase 2 clinical trial of LM11A-31 for AD, featured on the cover of *TIME* magazine in 2016. The work was supported by a NIH-NINDS F30 grant.

**2018 - 2021: *Management of Acute Seizures in the Pediatric Epilepsy Monitoring Unit.***  
**Mentor/senior author.**

Stanford Neurology chief resident Dr. Sara Pavitt and I, in collaboration with the Stanford/LPCH Brain and Behavior Nursing Group and Pediatric Epilepsy Chief Dr. Brenda Porter, led a quality improvement effort to standardize the management of acute seizures in the pediatric Epilepsy Monitoring Unit (EMU) at Lucile Packard Children's Hospital / Stanford Children's Health. Such safety measures are particularly imperative in Phase 1 EMU patients, who are admitted expressly for the purpose of eliciting and recording seizures on video EEG for surgical planning;

provoking measures such as medication cessation are often used, putting these patients at risk for complications including status epilepticus. We implemented a standardized seizure management protocol, including didactic teaching of nursing staff, posting of the protocol in the room of all EMU patients, and other iterative improvements by the physician/nursing team. Following this, in Phase 1 study patients, the number of seizures that are managed in full accordance with national safety and quality standards (including providing rapid seizure first aid and brief neurologic assessment) significantly increased from 40% to 90%, along with an increase in self-reported nursing confidence with seizure management. These data were presented at the 2020 Child Neurology Society meeting, and this work is published in *Hospital Pediatrics*.

## **Trainees**

**Currently, I mentor 3 research assistants and 6 undergraduate students in my independent laboratory.**

### **Past trainees:**

#### **Dr. Amanda Sandoval Karamian (2018-2020)**

Project: *Aberrant White Matter in Neonates with Nonstructural Epilepsy*

Dr. Sandoval Karamian was awarded a **Neurosciences Research Scholars Track** fellowship, entitling her to 6 months protected research time during residency to perform this work. This work resulted in a publication in *Epilepsia*.

Position: Epilepsy fellow at the Children's Hospital of Philadelphia.

#### **Dr. Sara Pavitt (2018-2020)**

Project: *Quality Improvement in the Pediatric Epilepsy Monitoring Unit*. Published in *Hospital Pediatrics*.

Current position: Assistant Professor, UT-Austin School of Medicine.

#### **Tristan Saucedo (2019- present)**

Project: *Maladaptive Myelination in Epilepsy*. Tristan was awarded a **2020 BioX Summer Undergraduate Fellowship** and a **2021 Stanford Undergraduate Major Grant** to continue this work.

Position: Stanford Undergraduate

#### **Eleanor Frost (2016-2020)**

Project: *Maladaptive Myelination in Epilepsy*. Eleanor was awarded a **2017 BioX Summer Undergraduate Fellowship** to continue this work.

Position: Graduated from Stanford with a co-terminal master's degree; applying to MD-PhD programs.

#### **Caroline Soane (2018-2019)**

Project: *Maladaptive Myelination in Epilepsy*.

Position: Graduated from Stanford; now a medical student at Vanderbilt University.

#### **Lydia Tam (2017-2018)**

Project: *Maladaptive Myelination in Epilepsy*.

Position: Graduated from Stanford; now a medical student at Stanford.

#### **Danielle Fraga (2016-2017)**

Project: *Maladaptive Myelination in Epilepsy*.



Position: Completed undergraduate and master's degree at Stanford, now a Study Data Manager at Genentech.

### **Other Teaching / Mentoring**

Invited to give Neurology lectures to Stanford medical students, 2019

Preceptor in Pediatric Neurology / Epilepsy resident/fellow clinic, 2019

"Pediatric Epilepsy Syndromes," Neurology residents didactic presentation, 2020

"Management of Pediatric Status Epilepticus," Neurology residents Boot Camp lecture series, 2017, 2018, 2020, 2021

### **Other Professional Experience**

Member, Child Neurology Society Research Committee, 2021 - present

Member, Scientific Program Committee, American Epilepsy Society, 2019 - present

Courses in Optical Fiber Photometry and CLARITY, laboratory of Dr. Karl Deisseroth at Stanford, 2018-2019

Stanford University Intensive Course on Clinical Research, 2018

#### **SCOPE Physician for Stanford Children's Hospital, 2012 - 2013**

Served as an advocate for a severely disabled child requiring multiple subspecialty care, including accompanying family to appointments, leading goals of care discussions and making home visits.

#### **Pack the Bag program, Ecumenical Hunger Program, 2011 - 2015**

My pediatrics residency class started this program to help school age children with food insecurity in East Palo Alto.

Mentor for high school students interested in careers in medicine (Woodside High School Woodside, CA), 2011-2012

Tutor for medical pharmacology course, UNC-Chapel Hill School of Medicine, 2004

Medical Student Mentoring Workshop, Association of University Professors of Neurology, 2004

#### **Co-President, UNC American Medical Women's Association, 2002 - 2004**

Our chapter organized a seminar series addressing issues pertaining to women in medicine and started a mentoring program pairing female medical students and senior female faculty members of UNC School of Medicine.

#### **Co-President, UNC Student Interest Group in Neurology, 2003 - 2004**

Organized a seminar series and mentoring program.

#### **Coordinator, UNC Student Health Action Coalition, 2002 - 2003**

UNC SHAC is the oldest student-run free health clinic in the US. I regularly led the weekly clinic, and led fundraising and community outreach efforts. Among other accomplishments, the committee I headed raised sufficient funds to establish the first SHAC Endowment Fund.

### **Professional Affiliations**

International Society for Neuroscience	2009 - present
American Academy of Neurology	2016 - present
American Epilepsy Society	2016 - present
American Clinical Neurophysiology Society	2018 - present
Child Neurology Society	2018 - present